OMNIPAQUE
As listed in the register: OMNIPAQUE 240 mg d'I/mL, solution injectable
518 mg · solution injectable
- Prescription only
- Active substance
- Iohexol
- Made by
- GE HEALTHCARE
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Iohexol). It describes the substance, not this exact product.
The iodine atoms in iohexol provide attenuation of X-rays in direct proportion to the concentration of iohexol.
Since concentration changes over time, iohexol provides time-dependent image contrast which may assist in visualizing body structures.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-06-30
Safety of the active substance
From the US prescribing label for the same active substance (Iohexol). It describes the substance, not this exact product.
WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION OF IOHEXOL INJECTION 140 mg IODINE/mL and 350 mg IODINE/mL Use only the iohexol, iodine concentrations and presentations recommended for intrathecal procedure [see Dosage and Administration (2.2, 2.8) ].
- Hysterosalpingography during pregnancy (or suspected pregnancy), menstruation (or when menstruation is imminent), within 6 months after termination of pregnancy, within 30 days after conization or curettage, when signs of infection are present in any portion of the genital tract, including the external genitalia and when reproductive tract neoplasia is known or suspected.
The most frequent adverse reactions (≥ 1%) were administration site pain (26%) and swelling (22%) in arthrography.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | GE HEALTHCARE |
|---|---|
| Active substance | Iohexol |
| Strength | 518 mg |
| Form | solution injectable |
| Route | intrathécale;intraveineuse |
| Dispensing (as stated by the register) | liste I |
| Marketed | Yes, according to the register |
| Authorisation procedure | Procédure nationale |
| Name in the register | OMNIPAQUE 240 mg d'I/mL, solution injectable |
| Packs | 1 flacon(s) polypropylène de 50 ml · 10 flacon(s) polypropylène de 50 ml |
| CIS | 66892062 |
| CIP13 | 3400934600500 |
| CIP13 | 3400956147298 |
Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician
Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).
Other strengths and forms
4 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.